KEYMED BIO-B (02162) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 499 million, representing a year-on-year increase of 812.1%. The loss attributable to shareholders was RMB 78.84 million, narrowing by 76.59% compared to the same period last year. Basic loss per share was RMB 0.3.

According to the announcement, during the reporting period, the Group's revenue comprised collaboration revenue and sales of spumacizumab (Kayerta). Collaboration revenue amounted to RMB 329 million, while spumacizumab sales reached RMB 169 million. Cost of sales included production costs of spumacizumab and costs arising from out-licensing collaboration arrangements.